At the upcoming World Vaccine Congress Asia 2013, Mr. Ysuyuki Ishii will be joining us as one of the many speakers. Hear about developing effective vaccine strategies to launch promising new generation vaccine candidates as Mr. Ishii introduces alpha-galactosylceramide (GalCer), a ligand for invariant natural killer T (iNKT) cells bridging between innate and adaptive immunity. He will also be presenting clinical applications of GalCer to immune disorder and transplantation and uncovering vaccine strategies using GalCer analogues for cancers and infectious diseases.
Mr. Yasuyuki Ishii is currently the Team Leader of the Laboratory for Vaccine Design at the RIKEN Research Center for Allergy and Immunology (RCAI), Japan. Prior to joining RIKEN, he worked as a Principal Investigator at the National Institute of Advanced Industrial Science and Technology (AIST), a Research Scientist of Immunochemistry at La Jolla Institute for Allergy and Immunology, USA as well as a Research Scientist at KIRIN brewery. Mr. Ishii holds an M.S. in Life-chemistry and a Ph.D from the Tokyo Institute of Technology.